AUG 06, 2020 10:00 AM PDT

Part VII: From biochemical nanosensors to imaging to informatics to COVID-19 convalescent plasma - developing diagnostics and therapies for clinical medicine

Speaker
  • Pathology Resident, Mount Sinai Hospital, Research Fellow, Massachusetts Institute of Technology, Co-Director of MIT COVID-19 Challenge, Massachusetts Institute of Technology
    BIOGRAPHY

Abstract

Current cancer management follows a multipronged approach that include surgery, radiation, and chemotherapy. There is a pressing need for a platform technology to provide precision chemotherapy screening, drug delivery detection, and real-time therapy efficacy monitoring. We have developed single walled carbon nanotube (SWNT) sensors for the detection of chemotherapeutics, more recently for temozolomide (TMZ) and its byproduct 5-Amino-4-imidazolecarboxamide (AIC) with sensitivity at 5-500 μM and in vitro viability up to 7 days in TMZ treated glioblastoma cells. Sensors for irinotecan, cisplatin, and lomustine were developed with sensitivities at 50 μM. H2O2 sensors were used to measure the therapy efficacy of gemcitabine and irinotecan in pancreatic ductal adenocarcinoma in vitro and in vivo. Multiplexing these sensors could yield insights into delivery, diffusion, metabolism, and efficacy of chemotherapeutics in hours or days. Other strategies are being developed such as ratiometric approaches and wavelength-induced frequency filtering to improve performance and sensitivity. A fiber optic platform was developed as a minimally invasive form factor to integrate the sensor hydrogel, optical waveguide, and detection system.

As a physician-scientist in NYC, my research rapidly shifted to the role of convalescent plasma (CP) in COVID-19. CP can be used to passively transfer antibodies from recently recovered patients to actively infected treatment-resistant patients. Initial studies revealed antibody neutralizing activity peaked at 31-35 days post symptom onset. Initial outcomes in severe and life-threatening COVID-19 hospitalized patients show CP as a potentially efficacious treatment for non-intubated patients. Retrospective study of 427 CP transfusion events yielded 12.9% of transfusion reaction rate with vast majority due to COVID-19 disease not CP. Increased risk was identified in patients with blood group B or cancer, and decreased risk for patients in their 80s


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
JUL 15, 2021 8:00 AM PDT
C.E. CREDITS
JUL 15, 2021 8:00 AM PDT
Date: July 15, 2021 Time: 8:00am (PDT), 11:00am (EDT) High dimensional full spectrum flow cytometry grants unprecedented access to previously unattainable parameters in cellular biology. Flu...
JUN 24, 2021 10:00 AM PDT
C.E. CREDITS
JUN 24, 2021 10:00 AM PDT
Date: June 24, 2021 Time: 10:00am PDT The Chan Zuckerberg Initiative (CZI) was founded to help solve some of society’s toughest challenges— from eradicating disease and improving...
Loading Comments...
Show Resources